Dorsomorphin (Compound C): Precision AMPK & BMP Pathway Inhibitor

Principles and Setup: Dual-Pathway Modulation with Dorsomorphin

Dorsomorphin (Compound C) is a reversible, cell-permeable, ATP-competitive AMPK inhibitor with exceptional selectivity (Ki = 109 nM) for AMP-activated protein kinase (AMPK) over structurally related kinases such as PKA, PKC, and JAK3. Uniquely, it also functions as a potent BMP signaling inhibitor by blocking phosphorylation of Smad1/5/8, thereby modulating both metabolic and developmental pathways. This dual functionality makes Dorsomorphin indispensable for dissecting complex cellular processes including energy homeostasis, autophagy regulation, neural stem cell differentiation, and iron metabolism modulation.

Mechanistically, Dorsomorphin’s inhibition of AMPK activity leads to the suppression of downstream targets such as acetyl-CoA carboxylase (ACC) phosphorylation (reduced by 80%), resulting in altered lipid metabolism, reduced autophagic proteolysis, and metabolic rewiring. Additionally, by interfering with BMP4-induced SMAD phosphorylation (IC₅₀ = 0.47 μM), Dorsomorphin efficiently blocks BMP/Smad signaling, influencing stem cell fate and tissue morphogenesis.

These properties position Dorsomorphin (Compound C) as a gold-standard tool for applied studies in metabolic disorders, cancer research, and developmental biology, as noted in comprehensive reviews such as "Dorsomorphin (Compound C): Precision AMPK Inhibitor for Experimental Biology", which highlights its reproducibility and pathway specificity.

Step-by-Step Experimental Workflows: Optimizing Dorsomorphin Use

Preparation and Solubilization

• Solubility: Dorsomorphin is insoluble in water and ethanol. Dissolve in DMSO (≥8.49 mg/mL) using gentle warming and ultrasonic treatment. Prepare fresh solutions immediately prior to use, as long-term storage of solutions is not recommended.
• Stock Storage: Store the solid product at -20°C. Maintain DMSO stocks at -20°C for short-term use, avoiding repeated freeze-thaw cycles.

Cell-Based Assays: Inhibition of AMPK and BMP/Smad Signaling

1. Cell Culture: Seed target cells (e.g., hepatocytes, HeLa, hESCs, or neural stem cells) to reach 60–80% confluency.
2. Treatment: Add Dorsomorphin at 4–40 μM final concentration. For AMPK inhibition, 10 μM is typical; for BMP/Smad pathway inhibition, use 5–20 μM depending on cell type and endpoint.
3. Assay Timing:
   • For AMPK/ACC phosphorylation inhibition, treat for 1–4 hours.
   • For BMP4-induced SMAD phosphorylation, pre-treat cells with Dorsomorphin for 30 minutes before BMP4 stimulation.
4. Readouts: Western blot for p-AMPK, p-ACC, SMAD1/5/8; qPCR for hepcidin or differentiation markers; metabolic flux assays for glycolysis and autophagy.

Animal Studies: Iron Metabolism and In Vivo Pathway Dissection

1. Dosage: Intraperitoneal injection at 10 mg/kg is standard in rodent models for acute pathway inhibition.
2. Endpoints: Monitor hepatic hepcidin mRNA, serum iron levels, bone formation, and tissue-specific phosphorylation status.

For advanced protocol enhancements and troubleshooting advice, the article "Dorsomorphin (Compound C): Precision AMPK & BMP Inhibition Protocols" provides complementary stepwise workflows tailored to metabolic and stem cell models.

Advanced Applications and Comparative Advantages

1. Cancer Research and Metabolic Pathway Dissection

Dorsomorphin’s high specificity for AMPK enables detailed studies into metabolic reprogramming in cancer cells. By inhibiting AMPK, investigators can assess the impact on tumor cell energy metabolism, autophagy regulation, and chemoresistance. For example, in hepatocyte models, inhibition of AMPK activity by Dorsomorphin leads to robust (>80%) suppression of ACC phosphorylation, directly altering lipid synthesis and growth signaling—a crucial aspect in cancer cell survival.

2. Neural Stem Cell Differentiation and BMP Pathway Inhibition

By blocking BMP-induced SMAD phosphorylation, Dorsomorphin promotes neural induction in human embryonic stem cells (hESCs), facilitating the generation of neural progenitors while suppressing alternative fates. This is pivotal for disease modeling and regenerative medicine applications. The dual action on AMPK and BMP/Smad signaling allows for fine-tuned control of stem cell fate and lineage commitment.

3. Iron Metabolism Modulation and Hepcidin Regulation

Dorsomorphin downregulates hepatic hepcidin transcription, resulting in increased serum iron. This property is leveraged in studies of systemic iron homeostasis and anemia of inflammation, where BMP/Smad signaling is central to hepcidin expression. Animal studies confirm that a 10 mg/kg dose reduces hepatic hepcidin mRNA and elevates serum iron, validating Dorsomorphin’s translational value.

4. Dissecting Glycolytic Rewiring in Bone and Development

In light of recent findings (You et al., 2024), metabolic regulators such as AMPK and BMP/Smad signaling play critical roles in bone formation by modulating glycolysis and O-GlcNAcylation. Dorsomorphin’s dual inhibition allows researchers to parse how suppression of these pathways impacts osteoblast differentiation, energy metabolism, and bone anabolism, providing mechanistic insights that extend the conclusions of the cited study.

For additional comparative data, see "Dorsomorphin (Compound C): ATP-Competitive AMPK & BMP Inhibitor in Metabolic and Stem Cell Pathways", which contrasts Dorsomorphin’s performance with alternative pathway inhibitors in advanced cellular and animal studies.

Troubleshooting & Optimization: Maximizing Experimental Reliability

• Compound Solubility: If precipitation occurs, confirm DMSO concentration and use ultrasonic treatment with gentle warming (≤40°C). Avoid vortexing, which can cause microbubble formation and compound loss.
• Cytotoxicity: At concentrations >40 μM, Dorsomorphin may induce off-target effects or cytotoxicity in sensitive cell types. Perform titration assays to determine the optimal minimal effective dose for your application.
• Batch Consistency: Always use high-purity preparations from trusted suppliers such as APExBIO to ensure batch-to-batch reproducibility.
• Timing of Addition: For BMP/Smad inhibition, pre-treat cells 30–60 minutes before ligand addition to ensure full pathway blockade. For AMPK inhibition, simultaneous or immediate pre-treatment is usually sufficient.
• Controls: Include DMSO-only and pathway-specific positive/negative controls to distinguish Dorsomorphin-specific effects from solvent or baseline activity.

For a detailed troubleshooting matrix and protocol refinements, the resource "Dorsomorphin (Compound C): Advanced AMPK Inhibitor Applications and Troubleshooting" delivers stepwise guidance on optimizing assay conditions across multiple models.

Future Outlook: Expanding Horizons for Dorsomorphin Research

As our understanding of metabolic and developmental signaling deepens, Dorsomorphin (Compound C) will continue to serve as a cornerstone for pathway dissection in both basic and translational research. Emerging studies, such as You et al. (2024), underscore the interplay between Wnt, BMP, and AMPK signaling in controlling osteoblastogenesis and metabolic flux, opening new avenues for therapeutic intervention in osteoporosis, cancer metabolism, and tissue regeneration.

Future directions include the integration of Dorsomorphin-mediated pathway inhibition with omics technologies, high-content screening, and single-cell analyses to unravel context-specific signaling networks. The ongoing refinement of stem cell differentiation protocols, metabolic reprogramming assays, and in vivo disease models will further leverage Dorsomorphin’s specificity and dual-pathway action to answer pressing biological questions.

For researchers seeking a robust, validated ATP-competitive AMPK inhibitor and BMP signaling inhibitor, Dorsomorphin (Compound C) from APExBIO remains the reagent of choice, ensuring reproducibility, reliability, and pathway precision in advanced biomedical studies.